CalciMedica, Inc. Common Stock
Save
37.34M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury.

Similar securities

Based on sector and market capitalization

Report issue